orphenadrine has been researched along with amantadine in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (61.54) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hecht, P; Kornhuber, J; Koutsilieri, E; Kroemer, RT; Liedl, KR; Riederer, P | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Mindham, RH | 1 |
| Postma, JU; Van Tilburg, W | 1 |
| Marsden, CD | 1 |
| Parkenberg, H | 1 |
| Costall, B; Naylor, RJ | 1 |
| Anstee, BH; Gaind, R; Mindham, RH; Rimmer, L | 1 |
| Florio, V; Longo, VG | 1 |
| Wheatley, D | 1 |
| Balster, RL; Harvey, SA; Nicholson, KL; Wiley, JL | 1 |
2 review(s) available for orphenadrine and amantadine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Advances in the management of parkinson's disease.
Topics: Amantadine; Anesthesia; Humans; Levodopa; Orphenadrine; Parasympatholytics; Parkinson Disease; Social Adjustment; Trihexyphenidyl | 1976 |
2 trial(s) available for orphenadrine and amantadine
| Article | Year |
|---|---|
Assessment of drugs in schizophrenia. Asessment of drug-induced extrapyramidal reactions and of drugs given for their control.
Topics: Amantadine; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Drug Evaluation; Fluphenazine; Humans; Orphenadrine; Parkinson Disease, Secondary; Piribedil; Procyclidine | 1976 |
Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism.
Topics: Affect; Amantadine; Basal Ganglia Diseases; Clinical Trials as Topic; Evaluation Studies as Topic; Female; Fluphenazine; Humans; Male; Orphenadrine; Parkinson Disease; Parkinson Disease, Secondary; Placebos; Schizophrenia | 1972 |
9 other study(ies) available for orphenadrine and amantadine
| Article | Year |
|---|---|
Quantitative analysis of the structural requirements for blockade of the N-methyl-D-aspartate receptor at the phencyclidine binding site.
Topics: Binding Sites; Excitatory Amino Acid Antagonists; Humans; Molecular Structure; Phencyclidine; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship | 1998 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Visual hallucinations and delirium during treatment with amantadine (Symmetrel).
Topics: Aged; Amantadine; Benztropine; Biperiden; Delirium; Drug Eruptions; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Orphenadrine; Parkinson Disease | 1975 |
[Treatment of parkinsonism].
Topics: Amantadine; Benztropine; Biperiden; Humans; Levodopa; Orphenadrine; Parkinson Disease; Procyclidine; Trihexyphenidyl | 1976 |
The relationship between the inhibition of dopamine uptake and the enhancement of amphetamine stereotypy.
Topics: Amantadine; Amphetamine; Animals; Behavior, Animal; Chlorpheniramine; Dopamine; Dopamine Antagonists; Drug Synergism; Histamine H1 Antagonists; Injections, Intraperitoneal; Male; Orphenadrine; Parasympatholytics; Parkinson Disease; Piperidines; Rats; Trihexyphenidyl | 1971 |
Effects of amantadine and of some synthetic antiparkinsonian drugs on the behavioral response to L-DOPA in mice.
Topics: Amantadine; Amitriptyline; Animals; Antiparkinson Agents; Atropine; Behavior, Animal; Dihydroxyphenylalanine; Diphenhydramine; Drug Synergism; Imipramine; Mice; Orphenadrine; Parasympatholytics; Pargyline; Trihexyphenidyl | 1971 |
Combined treatment in Parkinson's disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Orphenadrine; Parkinson Disease | 1983 |
Affinity and specificity of N-methyl- D-aspartate channel blockers affect their ability to disrupt prepulse inhibition of acoustic startle in rats.
Topics: Acoustic Stimulation; Adrenergic Uptake Inhibitors; Alanine; Amantadine; Animals; Binding Sites; Desipramine; Dextromethorphan; Dextrorphan; Dizocilpine Maleate; Dopamine Agents; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Ibogaine; Loudness Perception; Male; Memantine; Muscarinic Antagonists; Neural Inhibition; Orphenadrine; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Reflex, Startle; Selective Serotonin Reuptake Inhibitors | 2003 |